货号（Catalog No.）
CSD00090
通用名INN
Briakinumab
纯度(Purity)
>95%
浓度( Concentration)
1mg/ml
Formulation
PBS buffer pH7.5
Source
CHO cells
内毒素(Endotoxin level)
Please contact with the lab for this information.
生物活性
产品描述(Description)
Briakinumab is a human anti-IL-12 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases. It targets and neutralize interleukin-12 and interleukin-23, two proteins associated with inflammation, such as pro-inflammatory interleukins or tumor necrosis factor- alpha. Briakinumab represents a novel approach to treating psoriasis, Multiple Sclerosis, Crohn’s Disease and other autoimmune and inflammatory disorders. As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe.Briakinumab targets and neutralizes interleukin-12 and interleukin-23.
别名(Alternative names)
ABT-874
靶点;物种(Specificity target name;species)
IL12B[Homo sapiens]
种类(Species)
Homo sapiens
受体鉴定(Receptor identification)
IgG1-lambda
化学信息
分子量(MV)
146500.00 Da
CAS
339308-60-0
存储条件(Storage)
store at -80°C
Note
For research use only. Not suitable for clinical or therapeutic use.
...
产品展厅
